Latest article
Lilly’s tirzepatide beats Ozempic in head-to-head kind 2 diabetes trial
Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Main Nations, Forecast & Prime Distributors Evaluation Citrus and Allied Essences Ltd., Biolandes SAS,...
Curated by Zion Market Research annual report on the Global Vegetable Oils Market provides an in-depth understanding of market size, definition, and potential. ...